Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on MBX Biosciences, Inc. (MBX – Research Report) today. The company’s shares ...
Investing1d
Trump tariffs and the freight industry: Stifel weighs in
Investing.com-- Stifel analysts said in a recent note that logistics and freight firms with exposure to North American trade were likely to see limited impact from President-elect Donald Trump’s ...